When less may not be best - The challenge of individualising antiviral therapy for chronic hepatitis C infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 3, 2009, Pages 330-332

  Knight, Virginia ^a   Sievert, William ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; DRUG DOSE COMPARISON; DRUG FORMULATION; EDITORIAL; GENOTYPE; HEPATITIS C; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 63049087125     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05788.x     Document Type: Editorial

References (20)

1. WHO. Hepatitis C-global Prevalence 2002. Cited 10 December 2008. Available from URL: http://www.who.int/mediacentre/factsheets/fs164/en/
2. Lindsay KL, Trepo C, Heintges T et al. A randomised, double blind trial comparing pegylated interferon alpha 2b to interferon alpha 2b as initial treatment for chronic hepatitis c. Hepatology 2001 34 : 395 403.
3. McHutchinson J, Sulkowski M. Scientific rationale and study design of the individualised dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 hepatitis C. J. Viral Hepat. 2008 15 : 475 81.
4. Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alpha 2b plus ribavirin compared with interferon alpha 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
5. Meyer-Wyss B, Rich P, Egger H et al. Comparison of two PEG-interferon alpha 2b doses (1.0 or 1.5 ug/kg) combined with ribavirin in interferon naïve patients with chronic hepatitis C and moderate fibrosis. J. Viral Hepat. 2006 13 : 457 65.
6. Sulkowski M, Lawitz E, Shiffman ML et al. Final results of the IDEAL (individualised dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIB study. J. Hepatol. 2008 48 (Suppl. 2 S370.
7. Kawaoka T, Kawakami Y, Tsuji K et al. Dose comparison study of pegylated interferon-α-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial. J. Gastroenterol. Hepatol. 2009 24 : 366 71.
8. Fried M, Hadziyannis SJ, Shiffman ML et al. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J. Hepatol. 2008 48 (Suppl. 2 S5.
9. Ferenci P, Fried M, Shiffman M et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha 2a (40KD)/ribavirin. J. Hepatol. 2005 43 : 425 33.
10. Bronowicki JP, Ouzan D, Asselah T et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa 2a plus ribavirin. Gastroenterology 2006 131 : 1040 8.
11. Jacobson I, Brown R, Freilich B et al. Peginterferon alfa 2b and weight-based or flat dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007 46 : 971 81.
12. Weiland O, Hollander A, Mattsson L et al. Lower than standard dose peg IFN alfa 2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight based ribavirin. J. Viral Hepat. 2008 15 : 641 5.
13. Yu M-L, Dai C-Y, Huang J-F et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C infection. Gut 2007 56 : 553 9.
14. Lagging M, Langeland N, Pedersen C et al. Randomised comparison of 12 or 24 weeks of peginterferon and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008 47 : 1837 45.
15. Howell C, Jeffers L, Hoofnagle J et al. Hepatitis C in African Americans: summary of workshop. Gastroenterology. 2000 119 : 1385 96.
16. Layden-Almer J, Ribeiro R, Wiley T et al. Viral dynamics and response differences in HCV infected African Americans and white patients treated with IFN and ribavirin. Hepatology 2003 37 : 1343 50.
17. Missiha S, Heathcote J, Arenovich T et al. Impact of Asian race on response to combination therapy with peginterferon alpha 2a and ribavirin in chronic hepatitis C. Am. J. Gastroenterology 2007 102 : 2181 8.
18. Freshwater D, O'Donnell K, Mutimer D. Inferior response of Asian vs. non Asian hepatitis C genotype 3 infection to combination antiviral therapy. J. Viral Hepat. 2008 15 : 115 19.
19. Dev AT, McCaw R, Sundarajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002 36 : 1259 65.
20. Cheng PN, Marcellin P, Bacon B et al. Racial differences in responses to interferon-beta 1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. J. Viral Hepat. 2004 11 : 418 26.